{{Infobox drug
| drug_name         =
| INN               =
| type              =<!-- empty -->
| IUPAC_name        = 1-[(2''R'',3''R'',4''S'',5''R'')-3,4-Dihydroxy-5-methyloxolan-2-yl]-5-fluoropyrimidine-2,4-dione
| image             = Doxifluridine.svg
| width = 150px
| alt               = 
| caption           =
<!-- Clinical data -->
| pronounce         =
| tradename         = 
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = <!-- A/B1/B2/B3/C/D/X -->
| pregnancy_AU_comment = 
| pregnancy_US      = <!-- A/B/C/D/X/N -->
| pregnancy_category= 
| routes_of_administration = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_DE = <!-- Anlage I, II, III -->
| legal_NZ = <!-- Class A, B, C -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_US = <!-- OTC/Rx-only/Schedule I, II, III, IV, V -->
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_status      = <!-- Free text -->
<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| metabolites       =
| onset             = 
| elimination_half-life = 
| duration_of_action =
| excretion         = 
<!-- Identifiers -->
| CAS_number        = 3094-09-5
| class             = 
| ATCvet            = 
| ATC_prefix        = <!-- 'none' if uncategorised -->
| ATC_suffix        = 
| PubChem           = 18343
| DrugBank          = 
| ChemSpiderID      = 17322
| synonyms = Doxyfluridine; 5'-Deoxy-5-fluorouridine; 5'-Fluoro-5'-deoxyuridine; 5'-dFUrd; 5'-DFUR
<!-- Chemical and physical data -->
| C=9|H=11|F=1|N=2|O=5
| StdInChI=1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)/t3-,5-,6-,8-/m1/s1
| StdInChIKey = ZWAOHEXOSAUJHY-ZIYNGMLESA-N
| smiles = C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O
}}

'''Doxifluridine''' is a second generation nucleoside [[structural analog|analog]] [[prodrug]] developed by Roche and used as a [[cytostatic agent]] in [[chemotherapy]] in several Asian countries including China and South Korea.<ref>{{Cite web | url = https://www.drugs.com/international/doxifluridine.html | title = Doxifluridine | publisher = [[drugs.com]]}}</ref> Doxifluridine is not FDA-approved for use in the USA. It is currently being evaluated in several clinical trials as a stand alone or combination therapy treatment.

==Generic names==
5'-deoxy-5'-fluorouridine, 5'-deoxy-5-fluorouridine, 5'-DFUR, 5'-fluoro-5'-deoxyuridine, doxifluridine, doxyfluridine, Furtulon, Ro 21-9738

==Biology==
[[5-fluorouracil]] (5-FU) is currently an FDA-approved antimetabolite. <ref name=" Shelton 2016">{{cite journal |vauthors=Shelton J, Lu X, Hollenbaugh JA, Cho JH, Amblard F, Schinazi RF | title = Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs | journal = Chem Rev | volume = 116 | issue = 23 | pages = 14379-14455 |date=Dec 2016 | pmid = 27960273 | doi = 10.1021/acs.chemrev.6b00209 }}</ref> 5-FU is normally administered intravenously to prevent its degradation by dihydropyrimidine dehydrogenase in the gut wall. Doxifluridine (5´-deoxy-5-fluorouridine) is a fluoropyrimidine derivative of 5-FU, thus a second-generation nucleoside prodrug. Doxifluridine was designed to improve oral bioavailability in order to avoid dihydropyrimidine dehydrogenase degradation in the digestive system.<ref name=" Schöffski 2004">{{cite journal |vauthors= Schöffski P| title = The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors | journal = Anticancer Drugs | volume = 15 | issue = 2 | pages = 85-106 |date=Feb 2004 | pmid = 15075664 }}</ref>  

Within a cell, pyrimidine nucleoside phosphorylase or thymidine phosphorylase can metabolize doxifluridine into 5-FU.<ref name=Ishikawa>{{Cite journal | pmid = 9485021| year = 1998| author1 = Ishikawa| first1 = T| title = Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts| journal = Cancer research| volume = 58| issue = 4| pages = 685–90| last2 = Sekiguchi| first2 = F| last3 = Fukase| first3 = Y| last4 = Sawada| first4 = N| last5 = Ishitsuka| first5 = H}}</ref><ref>{{Cite web|url=https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=481255|title=Definition of Doxifluridine|publisher=[[National Cancer Institute]]|work=NCI Drug Dictionary}}</ref> It is also a metabolite of [[capecitabine]].<ref name=Ishikawa/> High levels of pyrimidine-nucleoside phosphorylase  and thymidine phosphorylase are expressed in esophageal, breast, cervical, pancreatic, and hepatic cancers.<ref name="Mori 2000">{{cite journal |vauthors= Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa-YS Chung K, Ikeda T, Takasaki K, Oka M, Kameyama M, Toi M, Fujii H, Kitamura M, Murai M, Sasaki H, Ozono S, Makuuchi H, Shimada Y, Onishi Y, Aoyagi S, Mizutani K, Ogawa M, Nakao A, Kinoshita H, Tono T, Imamoto H, Nakashima Y, Manabe T | title = Expression levels of thymidine phosphorylase and dihyropyrimidine dehydrogenase in various human tumor tissues | journal = Int J Oncol | volume = 17 | issue = 1 | pages = 33-8 |date= Jul 2000 | pmid = 10853015 }}</ref><ref name=" Ogata 2007 ">{{cite journal |vauthors= Ogata Y, Sasatomi T, Mori S, Matono K, Ishibashi N, Akagi Y, Fukushima T, Murakami H, Ushijima M, Shirouzu K | title = Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma | journal = Anticancer Res | volume = 27 | issue = 4C | pages = 2605-11 |date=Jul 2007 | pmid = 17695422 }}</ref> Liberation of 5-FU is the active metabolite and leads to inhibition of DNA synthesis and cell death.  

==Side effects==
High thymidine phosphorylase expression is also found in the human intestinal tract, resulting in dose-limiting toxicity (diarrhea) in some individuals.<ref name=" Lamont 1999 ">{{cite journal |vauthors= Lamont EB, Schilsky RL | title = The oral fluoropyrimidies in cancer chemotherapy | journal = Clin Cancer Res | volume = 5 | issue = 9 | pages = 2289-96 |date=Sep 1999 | pmid = 10499595 }}</ref>  

The most frequent adverse effects for doxifluridine were neurotoxicity and mucositis.

==Brand names==
Ai Feng - Hengrui, China; Didox - Shin Poong, South Korea; Doxifluridine-XinShiDai Pharm - XinShiDai Pharmaceutical, China; Doxyfluridine Kwangdong - Kwang Dong, South Korea; Furtulon - Roche, China; Ke Fu - Zhaohui, China; Ke Tuo - Southwest, China; Qi Nuo Bi Tong - Wanjie High-Tech, China; Shu Qi - Team, China; Tan Nuo- Xinchang Medicine & Chemical Co Ltd, China; Yi Di An - Pacific, China

==References==
{{reflist|30em}}

[[Category:Antineoplastic drugs]]
[[Category:Nucleosides]]
[[Category:Organofluorides]]